MA
NVO

Mezzasalma Advisors’s Novo Nordisk NVO Stock Holding History

Mezzasalma Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,126
Closed -$673K – 169
2025
Q3 		$673K Sell
12,126
-2,113
-15% -$124K 0.17% 78
2025
Q2 		$983K Sell
14,239
-1,855
-12% -$126K 0.3% 52
2025
Q1 		$1.12M Sell
16,094
-1,767
-10% -$146K 0.39% 46
2024
Q4 		$1.54M Sell
17,861
-6,146
-26% -$665K 0.5% 38
2024
Q3 		$2.86M Buy
24,007
+1,085
+5% +$145K 1.13% 27
2024
Q2 		$3.27M Buy
22,922
+11,022
+93% +$1.46M 1.4% 19
2024
Q1 		$1.53M Buy
+11,900
New +$1.42M 0.72% 30

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mezzasalma Advisors's NVO Position: Q4 2025 in Review

Mezzasalma Advisors sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 12,126 shares — an estimated $673K sold.

Mezzasalma Advisors first reported a position in NVO in Q1 2024 and held it in 7 quarters. The position peaked at $3.27M in Q2 2024. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Mezzasalma Advisors reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Mezzasalma Advisors sold 12,126 Novo Nordisk shares in Q4 2025, an estimated $673K.
  • Mezzasalma Advisors first reported a position in Novo Nordisk in Q1 2024 and held it in 7 quarters.
  • Mezzasalma Advisors's Novo Nordisk position peaked at $3.27M in Q2 2024.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Mezzasalma Advisors's 13F filing for Q4 2025, filed 21 Jan 2026.